Financial Performance - Revenue for the six months ended June 30, 2021, was RM 56,772,000, a decrease of 3.1% compared to RM 58,573,000 for the same period in 2020[10]. - Gross profit for the same period was RM 13,382,000, slightly up from RM 13,256,000 in 2020, indicating a marginal increase of 0.9%[10]. - Profit before tax increased significantly to RM 8,164,000, up 58.9% from RM 5,138,000 in the previous year[10]. - Net profit attributable to equity holders for the period was RM 5,829,000, compared to RM 2,828,000 in 2020, representing a growth of 106.5%[10]. - Total comprehensive income for the period was RM 6,791,000, a substantial increase from RM 1,741,000 in the same period last year[10]. - The company reported a basic and diluted earnings per share of 1.17 sen, compared to 0.69 sen in the previous year, marking an increase of 69.6%[10]. - For the six months ended June 30, 2021, the company reported a profit of 5,829 thousand MYR, compared to 2,828 thousand MYR for the same period in 2020, representing a 106% increase[16]. - The total comprehensive income for the six months ended June 30, 2021, was 6,791 thousand MYR, up from 1,741 thousand MYR in the previous year, indicating a significant growth of 289%[16]. Cash Flow and Assets - Cash and cash equivalents increased to RM 28,776,000 from RM 15,171,000, showing a growth of 89.9%[12]. - Current assets net worth stood at RM 133,424,000, up from RM 126,624,000, reflecting a growth of 5.6%[12]. - Total assets less current liabilities increased to RM 148,144,000 from RM 141,349,000, indicating a growth of 4.0%[12]. - The operating cash flow before changes in working capital for the six months ended June 30, 2021, was 8,996 thousand MYR, compared to 4,647 thousand MYR in 2020, reflecting an increase of 93%[19]. - The net cash generated from operating activities for the six months ended June 30, 2021, was 9,760 thousand MYR, a substantial rise from 2,477 thousand MYR in the same period last year, marking a 294% increase[19]. - The company’s cash and cash equivalents at the end of the reporting period were 28,776 thousand MYR, compared to 36,864 thousand MYR at the end of the previous year, showing a decrease of 22%[22]. Revenue Breakdown - Total revenue for the six months ended June 30, 2021, was RM 56,772 thousand, a decrease of 3% from RM 58,573 thousand for the same period in 2020[96]. - Distribution revenue increased to RM 40,262 thousand, up 9% from RM 37,046 thousand in the previous year[96]. - Production revenue decreased to RM 16,510 thousand, down 23% from RM 21,527 thousand in the same period last year[96]. - The decrease in manufacturing revenue was primarily due to a reduction of approximately 3.7 million MYR in sales of vitamin premixes to overseas customers[173]. - The increase in distribution revenue was mainly driven by a rise in sales of health products, particularly a tea product launched in December 2020, which saw an increase of approximately 3.0 million MYR[175]. Expenses and Costs - Total employee costs decreased to RM 2,763,000 in 2021 from RM 2,822,000 in 2020, a reduction of 2.1%[99]. - The total tax expense for the six months ended June 30, 2021, was RM 2,335,000, slightly higher than RM 2,310,000 in 2020, an increase of 1.1%[101]. - The total depreciation expense for the six months ended June 30, 2021, was RM 751,000, compared to RM 632,000 in 2020, an increase of 18.8%[99]. - Sales and distribution costs increased to approximately 1.2 million MYR, an increase of about 0.1 million MYR or 10.0% compared to 1.1 million MYR in the same period last year, primarily due to marketing activities for the newly launched tea[178]. - Administrative and other operating expenses rose to approximately 5.0 million MYR, an increase of about 1.1 million MYR or 30.6% from 3.9 million MYR in the previous year, mainly due to increased professional fees for compliance purposes post-IPO and foreign exchange losses[179]. Strategic Focus and Future Outlook - The company continues to focus on expanding its market presence and enhancing product offerings to drive future growth[10]. - The company plans to continue focusing on its core segments of animal feed additives and human food ingredients for future growth[32]. - The company is actively exploring new growth and expansion opportunities both locally and internationally in response to the pandemic[172]. - The company’s wholly-owned subsidiary entered into a cooperation agreement with a health biotechnology company, establishing a new indirect subsidiary in Hainan[172]. - The company believes that the pandemic will soon be well-controlled, allowing for smoother economic activities[172]. Shareholder Returns - The company did not declare an interim dividend for the six months ended June 30, 2021, consistent with the previous year[108]. - The board of directors decided not to declare any interim dividend for the six months ended June 30, 2021, consistent with the previous year[195].
利特米(01936) - 2021 - 中期财报